Recursion Pharmaceuticals, Inc. (RXRX)
4.58
-0.20
(-4.18%)
USD |
NASDAQ |
Oct 06, 11:14
Recursion Pharmaceuticals Max Drawdown (5Y) : 93.13% for Sept. 30, 2026
Max Drawdown (5Y) Chart
Historical Max Drawdown (5Y) Data
| Date | Value |
|---|---|
| September 30, 2026 | 93.13% |
| August 31, 2026 | 93.13% |
| July 31, 2026 | 93.13% |
| June 30, 2026 | 93.13% |
| May 31, 2026 | 93.13% |
| April 30, 2026 | 93.13% |
| March 31, 2026 | 93.13% |
| February 28, 2026 | 91.75% |
| January 31, 2026 | 90.68% |
| Date | Value |
|---|---|
| December 31, 2025 | 90.68% |
| November 30, 2025 | 90.68% |
| October 31, 2025 | 90.39% |
| September 30, 2025 | 90.39% |
| August 31, 2025 | 90.39% |
| July 31, 2025 | 90.39% |
| June 30, 2025 | 90.39% |
| May 31, 2025 | 90.39% |
Max Drawdown Definition
Max drawdown is an indicator of the risk of a portfolio chosen based on a certain strategy. It measures the largest single drop from peak to bottom in the value of a portfolio before a new peak is achieved.
Max Drawdown (5Y) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Max Drawdown (5Y) Benchmarks
| Editas Medicine, Inc. | 98.92% |
| Amgen, Inc. | 24.86% |
| Halozyme Therapeutics, Inc. | 49.06% |
| Novavax, Inc. | 98.82% |
| AVITA Medical, Inc. | 88.49% |
Max Drawdown (5Y) Related Metrics
| Alpha (5Y) | -43.23 |
| Beta (5Y) | 1.037 |
| Annualized Standard Deviation of Monthly Returns (5Y Lookback) | 81.60% |
| Historical Sharpe Ratio (5Y) | -0.4027 |
| Historical Sortino (5Y) | -0.9125 |
| Monthly Value at Risk (VaR) 5% (5Y Lookback) | 30.89% |